CN100579968C - 喹唑啉酮衍生物及其作为cb激动剂的应用 - Google Patents

喹唑啉酮衍生物及其作为cb激动剂的应用 Download PDF

Info

Publication number
CN100579968C
CN100579968C CN03803448A CN03803448A CN100579968C CN 100579968 C CN100579968 C CN 100579968C CN 03803448 A CN03803448 A CN 03803448A CN 03803448 A CN03803448 A CN 03803448A CN 100579968 C CN100579968 C CN 100579968C
Authority
CN
China
Prior art keywords
compound
formula
alkyl
dimethyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN03803448A
Other languages
English (en)
Chinese (zh)
Other versions
CN1628104A (zh
Inventor
C·T·布雷恩
E·K·齐亚杜卢艾斯
T·W·哈特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0202755A external-priority patent/GB0202755D0/en
Priority claimed from GB0213285A external-priority patent/GB0213285D0/en
Priority claimed from GB0221460A external-priority patent/GB0221460D0/en
Priority claimed from GB0221459A external-priority patent/GB0221459D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1628104A publication Critical patent/CN1628104A/zh
Application granted granted Critical
Publication of CN100579968C publication Critical patent/CN100579968C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN03803448A 2002-02-06 2003-02-05 喹唑啉酮衍生物及其作为cb激动剂的应用 Expired - Fee Related CN100579968C (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB0202755.5 2002-02-06
GB0202755A GB0202755D0 (en) 2002-02-06 2002-02-06 Organic compounds
GB0213285.0 2002-06-10
GB0213285A GB0213285D0 (en) 2002-06-10 2002-06-10 Organic compound
GB0221460.9 2002-09-16
GB0221460A GB0221460D0 (en) 2002-09-16 2002-09-16 Organic compound
GB0221459.1 2002-09-16
GB0221459A GB0221459D0 (en) 2002-09-16 2002-09-16 Organic compound

Publications (2)

Publication Number Publication Date
CN1628104A CN1628104A (zh) 2005-06-15
CN100579968C true CN100579968C (zh) 2010-01-13

Family

ID=27739227

Family Applications (1)

Application Number Title Priority Date Filing Date
CN03803448A Expired - Fee Related CN100579968C (zh) 2002-02-06 2003-02-05 喹唑啉酮衍生物及其作为cb激动剂的应用

Country Status (21)

Country Link
US (2) US20050085493A1 (enExample)
EP (2) EP1472234B1 (enExample)
JP (2) JP4428479B2 (enExample)
KR (1) KR100954626B1 (enExample)
CN (1) CN100579968C (enExample)
AR (1) AR038483A1 (enExample)
AT (1) ATE551329T1 (enExample)
AU (1) AU2003210212A1 (enExample)
BR (1) BR0307461A (enExample)
CA (1) CA2471974C (enExample)
CO (1) CO5601021A2 (enExample)
EC (1) ECSP045219A (enExample)
ES (1) ES2384967T3 (enExample)
MX (1) MXPA04007641A (enExample)
MY (1) MY143958A (enExample)
NO (1) NO328305B1 (enExample)
NZ (1) NZ571615A (enExample)
PE (1) PE20030867A1 (enExample)
PL (1) PL370657A1 (enExample)
TW (1) TW200306839A (enExample)
WO (1) WO2003066603A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109796360A (zh) * 2019-01-30 2019-05-24 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055153A1 (en) 1999-03-17 2000-09-21 Astrazeneca Ab Amide derivatives
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
GB0324790D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
JP2007510649A (ja) 2003-11-04 2007-04-26 メルク　エンド　カムパニー　インコーポレーテッド 置換ナフチリジノン誘導体
SE0303491D0 (sv) * 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
CN100506802C (zh) * 2004-06-04 2009-07-01 中国科学院上海药物研究所 一类甲酰肽样受体-1调节剂、其制备方法和用途
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds
EP1904068A1 (en) * 2005-07-11 2008-04-02 N.V. Organon Synergistic combination for the treatment of pain (cannabioid receptor agonist and opiod receptor agonist)
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20090209536A1 (en) * 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
FR2944013B1 (fr) * 2009-04-07 2011-07-15 Sanofi Aventis Derives de 1-alkyl-cinnolin-4(1h)-one substitues,leur preparation et leur application en therapeutique.
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CN104271579A (zh) 2012-05-03 2015-01-07 诺华股份有限公司 作为生长素释放肽受体激动剂的2,7-二氮杂-螺[4,5]癸烷-7-基衍生物的l-苹果酸盐及其结晶
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106146414A (zh) * 2016-07-07 2016-11-23 浙江大学 喹唑啉二酮类衍生物及其制备方法和用途
CN106831502A (zh) * 2017-03-13 2017-06-13 苏州市泽宸贸易有限公司 邻硝基苯磺酰氯、其合成方法及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2040927A (en) * 1978-12-19 1980-09-03 Ishikawa M Pharmaceutically active 3 - aromatic moiety substituted - 4 (3h) - quinazolinone derivatives
US4451467A (en) * 1981-01-16 1984-05-29 Masayuki Ishikawa 4(3H)-Quinazolinone derivatives, process for production thereof, and pharmaceutical compositions comprising said compounds

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR6200M (enExample) 1967-04-18 1968-07-22
DE1803210A1 (de) 1968-10-16 1970-05-14 Troponwerke Dinklage & Co 2-Methyl-3-(3-[4-phenylpiperazinyl-(1)]-2-hydroxypropyl)-chinazolinon-(4) und Verfahren zu seiner Herstellung
JPS5657768A (en) * 1979-10-18 1981-05-20 Masayuki Ishikawa Novel 4-quinazolone derivative substituted by aromatic residue at 3-position
JPS57118570A (en) * 1981-01-16 1982-07-23 Masayuki Ishikawa Novel 3-phenyl-4-quinazolone derivative
EP0639986A1 (en) * 1992-05-13 1995-03-01 Alcon Laboratories, Inc. Topical ophthalmic compositions comprising a combination of calcium antagonists with known antiglaucoma agents
US6017919A (en) 1996-02-06 2000-01-25 Japan Tobacco Inc. Compounds and pharmaceutical use thereof
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
SE0303491D0 (sv) 2003-12-19 2003-12-19 Astrazeneca Ab New use VI
GB0413618D0 (en) * 2004-06-17 2004-07-21 Novartis Ag Organic compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2040927A (en) * 1978-12-19 1980-09-03 Ishikawa M Pharmaceutically active 3 - aromatic moiety substituted - 4 (3h) - quinazolinone derivatives
US4451467A (en) * 1981-01-16 1984-05-29 Masayuki Ishikawa 4(3H)-Quinazolinone derivatives, process for production thereof, and pharmaceutical compositions comprising said compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NEW HYPOTENSIVE GAENTS. MASAYUKI ISHIKAWA ET AL.CHEMICAL AND PHARMACEUTICAL BULLETIN,Vol.30 No.2. 1982 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109796360A (zh) * 2019-01-30 2019-05-24 上海阿拉丁生化科技股份有限公司 一种3-氨基-2-萘甲酸类化合物的制备工艺

Also Published As

Publication number Publication date
US8552015B2 (en) 2013-10-08
NO20043580D0 (no) 2004-08-27
CN1628104A (zh) 2005-06-15
EP1472234B1 (en) 2012-03-28
JP2009149658A (ja) 2009-07-09
BR0307461A (pt) 2004-11-09
NO328305B1 (no) 2010-01-25
ATE551329T1 (de) 2012-04-15
AR038483A1 (es) 2005-01-19
EP2319839A1 (en) 2011-05-11
US20050085493A1 (en) 2005-04-21
JP4428479B2 (ja) 2010-03-10
US20070265285A1 (en) 2007-11-15
KR100954626B1 (ko) 2010-04-27
CO5601021A2 (es) 2006-01-31
WO2003066603A1 (en) 2003-08-14
NZ571615A (en) 2010-01-29
AU2003210212A1 (en) 2003-09-02
TW200306839A (en) 2003-12-01
NO20043580L (no) 2004-09-21
CA2471974A1 (en) 2003-08-14
ES2384967T3 (es) 2012-07-16
ECSP045219A (es) 2004-09-28
EP1472234A1 (en) 2004-11-03
PL370657A1 (en) 2005-05-30
MY143958A (en) 2011-07-29
KR20040083501A (ko) 2004-10-02
PE20030867A1 (es) 2003-12-04
HK1079518A1 (zh) 2006-04-07
CA2471974C (en) 2011-11-22
MXPA04007641A (es) 2004-11-10
JP2005522439A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
CN100579968C (zh) 喹唑啉酮衍生物及其作为cb激动剂的应用
US11130731B2 (en) Sulfonylureas and related compounds and use of same
JP3814125B2 (ja) ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
CN1956721B (zh) 用作辣椒素拮抗剂的喹唑啉酮衍生物
SK285703B6 (sk) 2-Aryl-8-oxodihydropurínový derivát, spôsob jeho prípravy, farmaceutický prostriedok s jeho obsahoma medziprodukt na jeho prípravu
JP2004517925A (ja) 血管新生制御剤としてのピリミジンアミン
WO2013013614A1 (zh) 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用
WO2007144625A1 (en) 2-oxo-2h-chromene compounds
TW201920123A (zh) 作為腺苷受體拮抗劑之喹㗁啉衍生物
CN101466690A (zh) (反-4-[({5-[(3,4-二氟苯基)氨基]-1,3,4-二唑-2-基}羰基)氨基]苯基)环己基)乙酸的晶型
JP2002507613A (ja) ピペリジン誘導体
JP2013525466A (ja) Ａｍｐｋのアクチベーターとして用いられるピロロ［３，２−ｄ］ピリミジン−３−イル誘導体
WO2019029295A1 (zh) 基于帕唑帕尼结构的hdac和vegfr双靶点抑制剂及其制备方法和应用
KR20000052876A (ko) 아미노산 수용체의 결합 부위에 친화력을 갖는 벤족사졸 유도체
HK1079518B (en) Quinazolinone derivatives and their use as cb agonists
JPH06211844A (ja) ベンゾフラン誘導体
ES2853981T3 (es) Un derivado de bencimidazol sustituido como un modulador de la actividad de TNF
AU2007202781B2 (en) Quinazolinone derivatives and their use as CB agonists
JPWO1998009960A1 (ja) ２，４−ジ置換ピリミジン誘導体、その製法およびそれを含有する医薬組成物
JPWO1996032383A1 (ja) 酢酸アミド誘導体、その製法及びそれを含有する医薬組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1079518

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1079518

Country of ref document: HK

C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel

Patentee after: Novartis Ag

Address before: Basel

Patentee before: Novartis AG

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20100113

Termination date: 20150205

EXPY Termination of patent right or utility model